Navigation Links
New way to kill lymphoma without chemotherapy

CHICAGO --- How do you annihilate lymphoma without using any drugs?

Starve it to death by depriving it of what appears to be a favorite food: HDL cholesterol.

Northwestern Medicine researchers discovered this with a new nanoparticle that acts like a secret double agent. It appears to the cancerous lymphoma cell like a preferred meal -- natural HDL. But when the particle engages the cell, it actually plugs it up and blocks cholesterol from entering. Deprived of an essential nutrient, the cell eventually dies.

A new study by C. Shad Thaxton, M.D., and Leo I. Gordon, M.D. shows that synthetic HDL nanoparticles killed B-cell lymphoma, the most common form of the disease, in cultured human cells, and inhibited human B-cell lymphoma tumor growth in mice.

The paper will be published Jan. 21 in the journal Proceedings of the National Academy of Sciences.

"This has the potential to eventually become a nontoxic treatment for B-cell lymphoma which does not involve chemotherapy," said Gordon, a co-corresponding author with Thaxton on the paper. "It's an exciting preliminary finding."

Gordon is a professor of medicine in hematology/oncology and Thaxton is an assistant professor of urology, both at Northwestern University Feinberg School of Medicine.

Gordon also is co-director of the hematologic malignancy program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and a physician at Northwestern Memorial Hospital. Thaxton is also a member of the Lurie Cancer Center.

Lymphoma Gobbles HDL Cholesterol

Recent studies have shown that B-cell lymphoma is dependent on the uptake of natural HDL -- short for high-density lipoprotein -- from which it derives fat content, such as cholesterol.

The nanoparticle -- originally developed by Thaxton as a possible therapy for heart disease -- closely mimics the size, shape and surface chemistry of natural HDL particles. But it has one key difference: a five nanometer gold particle at its core. Thus, when the nanoparticle is incubated with human B-cell lymphoma cells or used to treat a mouse with the human tumor, it socks lymphoma with a double whammy. After it attaches to the lymphoma cell, the gold particle's spongy surface sucks out its cholesterol while the gold core prevents the cell from absorbing more cholesterol typically carried in the core of natural HDL particles.

The lymphoma research showed Thaxton that the HDL nanoparticle had more than one trick up its golden sleeve.

"At first I was heavily focused on developing nanoparticles that could remove cholesterol from cells, especially those involved in heart disease," Thaxton said. "The lymphoma work has broadened this focus to how the HDL nanoparticles impact both the removal and uptake of cholesterol by cells. We discovered the particles are multi-taskers."

The Northwestern study also showed that natural HDL did not kill the cells or inhibit tumor growth. The nanoparticle was essential to starve the lymphoma cell.

Detour From Heart Disease to Cancer Killer

After developing the HDL nanoparticle, Thaxton gave a lecture in 2010 to Feinberg faculty. Gordon was in the audience. He knew that patients with advanced forms of B-cell lymphoma sometimes have dropping levels of cholesterol. A long-time lymphoma researcher and oncologist, Gordon was looking for new methods to deliver drugs to patients. He contacted Thaxton and they began to collaborate.

They tested the HDL nanoparticle alone and the HDL nanoparticle transporting cancer drugs. Surprisingly, the nanoparticle without drugs was just as effective at killing the B-cell lymphoma cells.

"We thought, 'That's odd. Why don't we need the drug?'" Gordon recalled.

That's when the scientists began delving into the mechanism by which the HDL nanoparticles were sticking to the HDL receptors on the lymphoma cell and manipulating cholesterol transport. In addition, patient samples analyzed by collaborators at Duke University for the study showed that lymphoma cells in patients had an overproduction of these HDL receptors compared to normal lymphocytes.

B-cell Lymphoma Most Common Lymphoma

The National Cancer Institutes reports that in 2012 there were about 70,000 new cases of non-Hodgkin lymphoma in the U.S. with nearly 19,000 deaths. About 90 percent of those new cases were B-cell lymphoma. Non-Hodgkin lymphoma is a cancer that starts in cells called lymphocytes, which are part of the body's immune system.

Why a Heart of Gold?

"Gold has a good track record of being compatible with biologic systems," Thaxton said.

Thaxton and Gordon are encouraged by their early data showing that the HDL nanoparticles do not appear toxic to other human cells normally targeted by HDLs, normal human lymphocytes or to mice. Also, because gold nanoparticles can be made in a discreet size and shape, they are excellent scaffolds for creating synthetic HDLs that closely mimic those found in nature.

"Like every new drug candidate, the HDL nanoparticle will need to undergo further testing," Thaxton noted.


Contact: Marla Paul
Northwestern University

Related biology news :

1. New research helps predict susceptibility to Burkitt lymphoma
2. Duke Medicine news -- Genome sequencing of Burkitt Lymphoma reveals unique mutation
3. New key element discovered in pathogenesis of Burkitt lymphoma
4. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
5. Solving puzzles without a picture
6. Not without my microbes
7. Bugs without borders
8. Production of FRP components without release agents
9. How bumblebees find efficient routes without a GPS
10. Surviving without ice
11. Survival without water: A key trait of an aquatic invader to spread
Post Your Comments:
(Date:11/9/2015)... , Nov. 09, 2015 ... addition of the "Global Law Enforcement ... offering. --> ) has ... Law Enforcement Biometrics Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that it has been selected ... of only three finalists for a 2015 Tekne ... category. The Tekne Awards honor Minnesota ... and leadership. iMedNet™ eClinical  technology ...
Breaking Biology News(10 mins):
(Date:12/1/2015)... ADDISON, Texas (PRWEB) , ... ... ... International , a leading relationship marketing company specializing in scientifically backed, age-defying ... magazine’s January 2016 issue, which highlights the exponential success and unrivaled opportunities ...
(Date:12/1/2015)... -- Cepheid (Nasdaq: CPHD ) today announced that, ... Healthcare Conference in New York City ... outlook for the fourth quarter of 2015 and initiating ... term business model expectations. John Bishop , ... be the fastest growing company of the major market ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... meeting this month and Dr. J. Kyle Mathews will join fellow ... the new single site hysterectomy. , An experienced urogynecologist, founder of Plano Urogynecology ...
(Date:12/1/2015)... , December 1, 2015 ... of the  "2016 U.K. Virology and Bacteriology ... for 100 Tests, Supplier Shares by Test, ... to their offering.  --> ... "2016 U.K. Virology and Bacteriology Testing Market: ...
Breaking Biology Technology: